

Dong-Hoe Koo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2353225/publications.pdf>

Version: 2024-02-01

60
papers

955
citations

430874
18
h-index

501196
28
g-index

62
all docs

62
docs citations

62
times ranked

1554
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical outcomes and prognostic factors of cone-beam CT-guided radiofrequency ablation for pulmonary metastases in colorectal cancer patients. Asia-Pacific Journal of Clinical Oncology, 2023, 19, .	1.1	1
2	Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients. Cancer, 2022, 128, 995-1003.	4.1	27
3	The first report of K-Umbrella Gastric Cancer Study: An open label, multi-center, randomized, biomarker-integrated trial for second-line treatment of advanced gastric cancer (AGC).. Journal of Clinical Oncology, 2022, 40, 4001-4001.	1.6	5
4	Prevalence and Predictive Factors for Upfront Dose Reduction of the First Cycle of First-Line Chemotherapy in Older Adults with Metastatic Solid Cancer: Korean Cancer Study Group (KCSG) Multicenter Study. Cancers, 2021, 13, 331.	3.7	4
5	Clinicopathological characteristics and outcomes of gastrointestinal stromal tumors with high progrenulin expression. PLoS ONE, 2021, 16, e0245153.	2.5	3
6	Value Frameworks: Adaptation of Korean Versions of Value Frameworks for Oncology. International Journal of Environmental Research and Public Health, 2021, 18, 3139.	2.6	4
7	Trends in Chemotherapy Patterns and Survival of Patients with Advanced Gastric Cancer over a 16-Year Period: Impact of Anti-HER2-Targeted Agent in the Real-World Setting. Cancer Research and Treatment, 2021, 53, 436-444.	3.0	4
8	A multi-institutional phase Ib/II trial of first-line triplet regimen (Pembrolizumab, Trastuzumab,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 467	1.6	31
9	Venous Invasion and Perineural Invasion as Upstaging and Poor Prognostic Factors in NO Gastric Cancers. Anticancer Research, 2021, 41, 5803-5810.	1.1	4
10	New prognostic model for patients with advanced gastric cancer: Fluoropyrimidine/platinum doublet for first-line chemotherapy. World Journal of Gastroenterology, 2021, 27, 8357-8369.	3.3	0
11	Prospective multicentre randomised clinical trial comparing survival rates, quality of life and nutritional status between advanced gastric cancer patients with different follow-up intensities: study protocol for the STOFOLUP trial. BMJ Open, 2021, 11, e056187.	1.9	3
12	Prognostic Value of Progranulin in Patients with Colorectal Cancer Treated with Curative Resection. Pathology and Oncology Research, 2020, 26, 397-404.	1.9	7
13	Middle-aged men with type 2 diabetes as potential candidates for pancreatic cancer screening: a 10-year nationwide population-based cohort study. Acta Diabetologica, 2020, 57, 197-202.	2.5	4
14	Prognostic significance of USP10 and p14ARF expression in patients with colorectal cancer. Pathology Research and Practice, 2020, 216, 152988.	2.3	17
15	Complications after 100 sessions of cone-beam computed tomography-guided lung radiofrequency ablation: a single-center, retrospective experience. International Journal of Hyperthermia, 2020, 37, 763-771.	2.5	5
16	Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: A multi-institutional phase Ib/II trial of first-line triplet regimen (pembrolizumab,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 24	1.6	24
17	Oncology, 2020, 38, 3081-3081.		
17	Pembrolizumab vs paclitaxel as second-line treatment for Asian patients with PD-L1- positive advanced gastric or gastroesophageal cancer (GC) in the phase III KEYNOTE-063 trial.. Journal of Clinical Oncology, 2020, 38, e16586-e16586.	1.6	3
18	Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting. Cancer Research and Treatment, 2020, 52, 907-916.	3.0	12

#	ARTICLE	IF	CITATIONS
19	Safety and efficacy of radiofrequency ablation for pulmonary metastases in metastatic colorectal cancer patients: A single center experience.. Journal of Clinical Oncology, 2020, 38, 141-141.	1.6	0
20	Neutrophil-to-lymphocyte ratio and risk of lung cancer mortality in a low-risk population: A cohort study. International Journal of Cancer, 2019, 145, 3267-3275.	5.1	41
21	The Incremental Risk of Pancreatic Cancer According to Fasting Glucose Levels: Nationwide Population-Based Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4594-4599.	3.6	22
22	Risk factors for incident anemia of chronic diseases: A cohort study. PLoS ONE, 2019, 14, e0216062.	2.5	8
23	Efficacy and safety of Viscum album extract (Helixor-M) to treat malignant pleural effusion in patients with lung cancer. Supportive Care in Cancer, 2019, 27, 1945-1949.	2.2	12
24	Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer. Cancer Research and Treatment, 2019, 51, 223-239.	3.0	13
25	Clinicopathological characteristics of patients with gastrointestinal stromal tumor according to progranulin expression.. Journal of Clinical Oncology, 2019, 37, 57-57.	1.6	1
26	Peri-tumor administration of 5-fluorouracil sol-gel using a hollow microneedle for treatment of gastric cancer. Drug Delivery, 2018, 25, 872-879.	5.7	19
27	Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG). Gastric Cancer, 2018, 21, 819-830.	5.3	24
28	Predicting cumulative incidence of adverse events in older patients with cancer undergoing first-line palliative chemotherapy: Korean Cancer Study Group (KCSG) multicentre prospective study. British Journal of Cancer, 2018, 118, 1169-1175.	6.4	25
29	Prognostic value of progranulin in patients with colorectal cancer underwent curative resection.. Journal of Clinical Oncology, 2018, 36, 696-696.	1.6	0
30	Clinical characteristics and outcomes of metastatic or recurrent gastric cancer with high progranulin expression in patients who had received palliative chemotherapy.. Journal of Clinical Oncology, 2018, 36, 83-83.	1.6	0
31	Initial titration with 200 µg fentanyl buccal tablets: a retrospective safety analysis in Korean cancer patients. Korean Journal of Internal Medicine, 2018, 33, 577-584.	1.7	2
32	The significance of the trial outcome was associated with publication rate and time to publication. Journal of Clinical Epidemiology, 2017, 84, 78-84.	5.0	27
33	Antiemetic Corticosteroid Rotation from Dexamethasone to Methylprednisolone to Prevent Dexamethasone-Induced Hiccup in Cancer Patients Treated with Chemotherapy: A Randomized, Single-Blind, Crossover Phase III Trial. Oncologist, 2017, 22, 1354-1361.	3.7	24
34	Practice Patterns Regarding Multidisciplinary Cancer Management and Suggestions for Further Refinement: Results from a National Survey in Korea. Cancer Research and Treatment, 2017, 49, 1164-1169.	3.0	8
35	Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor. Cancer Research and Treatment, 2016, 48, 1155-1166.	3.0	142
36	Progranulin as a predictive factor of response to chemotherapy in advanced biliary tract carcinoma. Cancer Chemotherapy and Pharmacology, 2016, 78, 1085-1092.	2.3	12

#	ARTICLE	IF	CITATIONS
37	Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 339-347.	2.3	4
38	Field Cancerization in Sporadic Colon Cancer. <i>Gut and Liver</i> , 2016, 10, 773-780.	2.9	30
39	Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 173-182.	2.3	37
40	Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer. <i>Tumor Biology</i> , 2015, 36, 5865-5871.	1.8	17
41	EGFR-TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 197-206.	2.3	26
42	Efficacy and safety of ifosfamide in combination with carboplatin and etoposide in small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 933-937.	2.3	3
43	Ethical Attitudes according to Education and Clinical Experience of Do-Not-Resuscitate (DNR). <i>The Korean Journal of Hospice and Palliative Care</i> , 2015, 18, 208-218.	0.7	1
44	A Rare Case of Acute Leukemic Presentation of Blastic Plasmacytoid Dendritic Cell Neoplasm without Cutaneous Lesions. <i>Annals of Laboratory Medicine</i> , 2014, 34, 148-151.	2.5	4
45	Serum CA19-9 as a prognostic factor in patients with metastatic gastric cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2013, 9, 324-330.	1.1	28
46	Diagnosis and Treatment of Gastrointestinal Stromal Tumor. <i>Korean Journal of Medicine</i> , 2013, 85, 341.	0.3	4
47	Burnt-out Metastatic Prostate Cancer. <i>Yeungnam University Journal of Medicine</i> , 2013, 30, 116.	0.1	0
48	Venous thromboembolism (VTE) in patients with advanced gastric cancer: An Asian experience. <i>European Journal of Cancer</i> , 2012, 48, 492-500.	2.8	38
49	Aggressive Classical Kaposi's Sarcoma Mimicking Malignant Lymphoma. <i>Pathology and Oncology Research</i> , 2012, 18, 1067-1069.	1.9	1
50	Progranulin as a Prognostic Biomarker for Breast Cancer Recurrence in Patients Who Had Hormone Receptor-Positive Tumors: A Cohort Study. <i>PLoS ONE</i> , 2012, 7, e39880.	2.5	44
51	Three-week combination chemotherapy with S-1 and cisplatin as first-line treatment in patients with advanced gastric cancer: a retrospective study with 159 patients. <i>Gastric Cancer</i> , 2012, 15, 305-312.	5.3	9
52	Prognostic Value of Immunohistochemical Biomarkers at Different Cut-off Values in Patients with Diffuse Large B-cell Lymphoma Treated with CHOP Chemotherapy. <i>Journal of Korean Medical Science</i> , 2011, 26, 1556.	2.5	8
53	A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: validation and comparison with previous models. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 913-921.	2.3	69
54	Systemic chemotherapy for treatment of advanced small bowel adenocarcinoma with prognostic factor analysis: retrospective study. <i>BMC Cancer</i> , 2011, 11, 205.	2.6	46

#	ARTICLE	IF	CITATIONS
55	Adjuvant Chemotherapy for Small Bowel Adenocarcinoma after Curative Surgery. <i>Oncology</i> , 2011, 80, 208-213.	1.9	21
56	Abstract 2238: Clinical characteristics and outcome of patients with Rituximab-CHOP resistant/refractory DLBCL: Presence of B symptom and high LDH at diagnosis predict survival. , 2011, , .		0
57	Pneumocystis jiroveci Pneumonia Mimicking Miliary Tuberculosis in a Kidney Transplanted Patient. <i>Tuberculosis and Respiratory Diseases</i> , 2009, 67, 127.	1.8	1
58	A Phase II Study of Cetuximab (Erbixux®) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer. <i>Journal of Korean Medical Science</i> , 2007, 22, S98.	2.5	12
59	Monoclonal Proteinuria as a Prognostic Factor for Multiple Myeloma Patients with Intact Immunoglobulin Type. <i>The Korean Journal of Hematology</i> , 2007, 42, 276.	0.7	0
60	Skin Necrosis after a Low-Dose Vasopressin Infusion through a Central Venous Catheter for Treating Septic Shock. <i>Korean Journal of Internal Medicine</i> , 2006, 21, 287.	1.7	14